

=> fil hcaplus  
 FILE 'HCAPLUS' ENTERED AT 12:11:07 ON 29 OCT 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 29 Oct 2002 VOL 137 ISS 18  
 FILE LAST UPDATED: 28 Oct 2002 (20021028/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=>


=> d stat que  
 L15 STR



VAR G4=CH/N  
 REP G5=(0-2) C  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RSPEC I  
 NUMBER OF NODES IS 18


STEREO ATTRIBUTES: NONE  
L16 STR



VAR G4=CH/N  
REP G5=(0-2) C  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RSPEC I  
NUMBER OF NODES IS 18


STEREO ATTRIBUTES: NONE  
L17 STR



VAR G4=CH/N  
REP G5=(0-2) C  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RSPEC I  
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE  
L18 STR



VAR G4=CH/N  
 REP G5=(0-2) C  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RSPEC I  
 NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L29 SCR 2039 OR 2127 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 O  
 R 2051 OR 2043  
 L31 17 SEA FILE=REGISTRY SSS FUL L15 OR L16 OR L18  
 L32 74 SEA FILE=REGISTRY SSS FUL L17 NOT L29  
 L33 79 SEA FILE=REGISTRY ABB=ON PLU=ON L31 OR L32  
 L34 83 SEA FILE=HCAPLUS ABB=ON PLU=ON L33  
 L35 12 SEA FILE=HCAPLUS ABB=ON PLU=ON L34 AND (BREAST(W) CANCER)

=> d ibib abs hitrn l35 1-12

L35 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2001:885714 HCAPLUS  
 DOCUMENT NUMBER: 136:11197  
 TITLE: Transdermal delivery of lasofoxifene  
 INVENTOR(S): Fikstad, David; Quan, Danyi  
 PATENT ASSIGNEE(S): Watson Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 23 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001091724	A2	20011206	WO 2001-US17567	20010531
WO 2001091724	A3	20020530		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,  
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,  
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 US 2002037311 A1 20020328 US 2001-871318 20010531  
 BR 2001006680 A 20020430 BR 2001-6680 20010531  
 EP 1229909 A2 20020814 EP 2001-939751 20010531  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2000-208789P P 20000601  
 WO 2001-US17567 W 20010531

AB The present invention provides methods, pharmaceutical formulations, and devices for the transdermal delivery lasofoxifene (CP-336156) and pharmaceutically acceptable salts. The invention also provides transdermal compns. of CP-336156 or its salts dissolved or dispersed in a suitable carrier vehicle, optionally contg. permeation enhancers and other excipients. The carrier vehicle may be a pressure sensitive adhesive, polymeric reservoir, or a fluid of controlled viscosity. The carrier vehicle may be contained in a device for purposes of holding the compn. against the skin surface. Such devices may be in the form of matrix patches (drug in adhesive) or reservoir patches (drug in a liq. or polymeric reservoir with peripheral, in-line, or over-layered pressure sensitive adhesive). Methods for treating pathologies assocd. with the binding of lasofoxifene with the human estrogen receptor are also disclosed. The invention formulations and devices are useful to treat or prevent bone loss, obesity, **breast cancer**, endometriosis, cardiovascular disease and prostatic disease. Thus, a transdermal matrix formulation was prepd. in a water-based acrylic pressure-sensitive adhesive with CP-336156 at 3%. A permeation-enhanced formulation was prepd. with 3% CP-336156 and 1.5% sodium lauroyl glycolate in the same adhesive. The mean enhancement factor was 2.2.

IT **180916-16-9**, Lasofoxifene  
 RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (transdermal delivery of lasofoxifene)

L35 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2001:762983 HCAPLUS  
 DOCUMENT NUMBER: 135:303769  
 TITLE: Preparation of estrogen agonist/antagonist metabolites  
 INVENTOR(S): Day, Wesley Warren; Johnson, Kim Anne; Prakash,  
 Chandra Aggarwal; Egglar, James Frederick  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: PCT Int. Appl., 80 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077093	A1	20011018	WO 2001-IB427	20010319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,				

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,  
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,  
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002042443 A1 20020411 US 2001-825980 20010404


US 6455572 B2 20020924

PRIORITY APPLN. INFO.:

US 2000-267198P P 20000407

OTHER SOURCE(S): MARPAT 135:303769

GI



I

AB This invention relates to compds. represented by formula [I; R1 = pyrrolidin-1-yl, 2-oxopyrrolidin-1-yl, 2-hydroxy-1-pyrrolidin-1-yl, 2-methoxy-1-pyrrolidin-1-yl, NH(CH2)3COR6 (where R6 = OH, NHCH2CO2H); R2, R3, R4, R7 = H, OH, OMe; provided that (a) if R1 is pyrrolidin-1-yl or NH(CH2)3CO2H, and (b) R2 is OH or OMe and R3 and R7 are H, or if R1 is defined in (a) and (c) R2 and R7 are H and R3 is OH or OMe, then R4 is not H] which are mammalian metabolites of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol (PPTN) and are believed to possess significant pharmacol. activities similar or identical to those possessed by the parent PPTN. The compds. of the invention can be used as stds. for anal. assays or as intermediates for the further chem. synthesis or biosynthesis of chem. entities. The invention also relates to pharmaceutical compns. for the treatment of disease and methods of treating disease. Examples of diseases or conditions for which the compds. can be effective include osteoporosis, **breast cancer**, hyperlipidemia, atherosclerosis, Alzheimer's disease, cataracts, loss of libido, male sexual dysfunction, colon cancer, skin wrinkles, autoimmune disease, alopecia, acne, cardiovascular disease, cataracts, diabetes, endometriosis, female sexual dysfunction, hyperglycemia, obesity, obsessive compulsive disorder, etc. (no data). Thus, 1-[2-[4-(2-Bromo-6,7-dimethoxy-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine was coupled with phenylboronic acid in the presence of tetrakis(triphenylphosphine)palladium and Na2CO3 in EtOH at room temp. for 10 h to give 1-[2-[4-(6,7-dimethoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine which was hydrogenated Pd(OH)2 on carbon in a mixt. of 2 N aq. HCl, H2O, and EtOH at 50.degree. under a H atm. of 30 psi to give 1-[2-[4-(6,7-dimethoxy-2-phenyl-1,2,3,4-

tetrahydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine. The latter compd. was heated in a mixt. of AcOH and 48% aq. HBr at 90.degree. for 2 h to give cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2,3-diol and a mixt. of cis-3-methoxy-7-phenyl-8-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol and cis-3-methoxy-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol.

IT **180916-16-9**

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(animal metab.; prepn. of metabolites of (-)-cis-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydronaphthalenol estrogen agonist/antagonist as therapeutic agents)

IT **366017-88-1P 366017-89-2P**

RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(metabolite in mice; prepn. of metabolites of (-)-cis-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydronaphthalenol estrogen agonist/antagonist as therapeutic agents)

IT **366017-69-8P 366017-70-1P 366017-71-2P**

**366017-81-4P 366017-82-5P 366017-83-6P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of metabolites of (-)-cis-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydronaphthalenol estrogen agonist/antagonist as therapeutic agents)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:559558 HCAPLUS

DOCUMENT NUMBER: 135:142234

TITLE: Compositions and methods for treating conditions responsive to estrogen

INVENTOR(S): Thompson, David Duane; Lee, Andrew George; Day, Wesley Warren; Rosati, Robert Louis

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 36 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1120114	A2	20010801	EP 2001-300221	20010111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2001041718	A1	20011115	US 2001-758778	20010111
JP 2001213776	A2	20010807	JP 2001-4452	20010112

PRIORITY APPLN. INFO.: US 2000-175752P P 20000112

OTHER SOURCE(S): MARPAT 135:142234

AB This invention relates to methods, pharmaceutical compns. and kits useful in treating conditions responsive to estrogen by the administration of estrogen agonists/antagonists. Conditions responsive to the compns. include rheumatoid arthritis, colon cancer, tissue wounds, skin wrinkles and cataracts. The compns. are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier or

diluent. The compns. and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects assocd. with estrogen administration. The in vitro antiproliferative effects of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol were tested in 2 types of human **breast cancer** cell lines: first, MCF-7 cells, which contain ER as well as progesterone receptors (PgR), and second, MDA-MB-231 cells, which lack ER and PgR, and enable the detn. of an effect that is independent of the ER mechanism. Growth inhibition was ER-specific and not due to cytotoxicity since the compd. had no measurable effect on the ER-neg. cell line.

IT 180915-78-0 180915-84-8 180915-86-0

180916-14-7 180916-16-9 193274-89-4

351527-09-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. for treating conditions responsive to estrogen)

L35 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:541600 HCAPLUS

DOCUMENT NUMBER: 135:117261

TITLE: Method using estrogen agonists/antagonists for reducing morbidity and the risk of mortality from cardiovascular disease, **breast cancer**, and osteoporosis

INVENTOR(S): Day, Wesley Warren; Lee, Andrew George; Thompson, David Duane

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 37 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1118323	A2	20010725	EP 2001-300159	20010109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2001056099	A1	20011227	US 2001-757817	20010110
JP 2001226265	A2	20010821	JP 2001-5300	20010112

PRIORITY APPLN. INFO.: US 2000-175663P P 20000112

OTHER SOURCE(S): MARPAT 135:117261

AB The invention discloses methods, pharmaceutical compns., and kits useful in reducing cardiovascular morbidity and the risk of mortality in men and post-menopausal women and morbidity and the risk of mortality in post-menopausal women from the combined redn. of **breast cancer**, osteoporosis and cardiovascular disease by the administration of estrogen agonists/antagonists. The compns. are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier, or diluent. The compns. and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects assocd. with estrogen administration.

IT 180916-16-9

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(estrogen agonists/antagonists for reducing morbidity and risk of mortality from cardiovascular disease, **breast cancer**, and osteoporosis)

IT **180915-78-0 180915-78-0D**, isomers, N-oxides, esters, and prodrug derivs. **180915-84-8 180915-84-8D**, isomers, N-oxides, esters, and prodrug derivs. **180915-86-0 180915-86-0D**, isomers, N-oxides, esters, and prodrug derivs. **180916-14-7 180916-14-7D**, isomers, N-oxides, esters, and prodrug derivs. **180916-15-8 180916-15-8D**, isomers, N-oxides, esters, and prodrug derivs. **180916-16-9D**, isomers, N-oxides, esters, and prodrug derivs. **193274-89-4 193274-89-4D**, isomers, N-oxides, esters, and prodrug derivs.  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(estrogen agonists/antagonists for reducing morbidity and risk of mortality from cardiovascular disease, **breast cancer**, and osteoporosis)

L35 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:488632 HCAPLUS

DOCUMENT NUMBER: 135:92550

TITLE: Preparation of tetrahydroisoquinolines as estrogen agonists/antagonists

INVENTOR(S): Chesworth, Richard; Cameron, Kimberly O'Keefe; Da Silva-Jardine, Paul Andrew; Day, Robert Francis; Lefker, Bruce Allen; Zawistoski, Michael Paul

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: Eur. Pat. Appl., 66 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1113007	A1	20010704	EP 2000-311197	20001214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2001039285	A1	20011108	US 2000-745396	20001221
JP 2001294575	A2	20011023	JP 2000-389883	20001222
BR 2000006265	A	20020305	BR 2000-6265	20001222


PRIORITY APPLN. INFO.: US 1999-173063P P 19991224

OTHER SOURCE(S): MARPAT 135:92550

GI



I



II



AB The title compds. [I; A1 = H, OH, alkoxy, etc.; A2-A4 = H, OH, alkoxy, halo; R1 = (un)substituted Ph, pyridyl, piperidinyl, etc.; X = a bond, (CH2)<sub>n</sub> (n = 1-3), CO2, etc.; R2 = alkyl, alkenyl, benzhydryl, etc.; p = 0-2], useful for treating or preventing obesity, **breast cancer**, osteoporosis, endometriosis, cardiovascular disease, prostatic disease, and the like, were prepd. Thus, hydrogenation of 1-[1-(4-benzyloxyphenyl)-6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-2,2,2-trifluoroethanone over 10% Pd/C in EtOH afforded 88% I [A1 = OMe; A2-A4 = H; R1 = 4-HOC6H4; p = 0; X = CO; R2 = CF3].

IT **347980-59-0P 347982-40-5P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of tetrahydroisoquinolines as estrogen agonists/antagonists)

IT **347980-26-1P 347980-32-9P 347980-37-4P**  
**347980-83-0P 347980-97-6P 347981-05-9P**  
**347981-50-4P 347982-52-9P 347982-63-2P**  
**347982-67-6P 347982-72-3P 347983-29-3P**  
**347983-34-0P 347983-38-4P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of tetrahydroisoquinolines as estrogen agonists/antagonists)

IT **347981-01-5**  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (prepn. of tetrahydroisoquinolines as estrogen agonists/antagonists)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:123186 HCAPLUS

DOCUMENT NUMBER: 134:173020

TITLE: Drugs containing estrogen agonists for treatment of osteoporosis, cardiovascular diseases, and **breast cancer**

INVENTOR(S): Yu, Julia Lee

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001048805	A2	20010220	JP 2000-222159	20000724
EP 1086692	A2	20010328	EP 2000-305611	20000703
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 2000048827	A5	20010201	AU 2000-48827	20000725
PRIORITY APPLN. INFO.:			US 1999-146072P	P 19990728
			US 1999-146075P	P 19990728

AB Prophylactic and/or therapeutic agents, which can treat the title diseases in patients undergoing therapy with warfarin (I) or propranolol (II)

without affecting actions of I or II, contain estrogen agonists such as lasofoxifene (III) and droloxifene (IV). Bindings of I and II by human plasma proteins were not affected by III or IV. Administration of III to 12,000 .gtoreq.60-yr-old women with high risk of **breast cancer** significantly prevented **breast cancer**.

IT **180916-16-9**, Lasofoxifene

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of osteoporosis, cardiovascular diseases, and **breast cancer** with estrogen agonists which do not interact with warfarin or propranolol)

L35 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:414063 HCAPLUS

DOCUMENT NUMBER: 127:34119

TITLE: Preparation of (-)-cis-(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate by optical resolution

INVENTOR(S): Chiu, Charles K.; Meltz, Morgan

PATENT ASSIGNEE(S): Pfizer Inc., USA; Chiu, Charles K.; Meltz, Morgan

SOURCE: PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9716434	A1	19970509	WO 1996-IB1049	19961004
W: AU, BG, BR, BY, CA, CN, CZ, HU, IL, IS, JP, KR, KZ, LK, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2236673	AA	19970509	CA 1996-2236673	19961004
AU 9669984	A1	19970522	AU 1996-69984	19961004
AU 708841	B2	19990812		
EP 876359	A1	19981111	EP 1996-931206	19961004
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LV, FI				
CN 1201458	A	19981209	CN 1996-198048	19961004
CN 1067065	B	20010613		
JP 11502866	T2	19990309	JP 1996-517180	19961004
BR 9611436	A	19990323	BR 1996-11436	19961004
JP 3088020	B2	20000918	JP 1997-517180	19961004
CZ 287341	B6	20001011	CZ 1998-1320	19961004
RU 2162465	C2	20010127	RU 1998-110128	19961004
IL 124027	A1	20011031	IL 1996-124027	19961004
SK 282172	B6	20011106	SK 1998-542	19961004
ZA 9609212	A	19980504	ZA 1996-9212	19961101
<u>US 5948809</u>	A	19990907	US 1998-65094	19980428
NO 9801962	A	19980430	NO 1998-1962	19980430
PRIORITY APPLN. INFO.:			US 1995-6125P P	19951102
			WO 1996-IB1049 W	19961004

GI



I

AB An advantageous process for the prepn. of (-)-cis-(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol [(5R,6S)-I] D-tartrate involves dissolving racemic or partially optically enriched I in boiling aq. ethanol to form a soln., adding an equal molar amt. of D-tartaric acid in aq. ethanol to above soln. to form a second soln., cooling the second soln., and collecting (5R,6S)-I D-tartrate. A method for treating osteoporosis, cardiovascular disease or hyperlipidemia, prostatic disease, obesity, **breast cancer**, or endometriosis or for lowering serum cholesterol level in an mammal comprises administering (5R,6S)-I D-tartrate to a mammal. Thus, 1-[2-[4-(2-bromo-6-methoxy-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine was coupled with phenylboronic acid in the presence of (Ph<sub>3</sub>P)<sub>4</sub>Pd and Na<sub>2</sub>CO<sub>3</sub> in THF under reflux for 2 h to give 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine hydrochloride (nafoxidine hydrochloride), which was hydrogenated over Pd(OH)<sub>2</sub> in MeOH/EtOH at 50.degree. and 50 psi for 68 h to give cis-1-[2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine. This was heated in a mixt. of HBr and AcOH at 100.degree. for 15 h followed by treating the hydrobromide salt in CHCl<sub>3</sub>/MeOH with satd. NaHCO<sub>3</sub> soln. to give racemic I. Racemic I (5 g) in a 95:5 mixt. of abs. ethanol/H<sub>2</sub>O (50 mL) was treated with a soln. of 1.83 g D-tartaric acid in a 95:5 mixt. of abs. ethanol/H<sub>2</sub>O (20 mL) and heated under gentle reflux to give a homogeneous soln., which was cooled and stirred at ambient temp. (.apprx.25.degree.) overnight. The salt pptd. out as a white solid, collected by suction filtration, washed with 20 mL abs. ethanol, and dried under vacuum to give 2.77 g (5R,6S)-I, which was recrystd. from the same solvent to give 2.48 g (5R,6S)-I with an optical purity of >99.1%. (5R,6S)-I D-tartrate was administered to rats by s.c. injection to decrease prostate wt.

IT **180915-78-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of (-)-cis-(5R,6S)-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydronaphthalen-2-ol D-tartrate by optical resolu. for disease treatment)

L35 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:551346 HCAPLUS

DOCUMENT NUMBER: 125:195446

TITLE: Preparation of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen

agonists/antagonists  
 INVENTOR(S): Cameron, Kimberly O.; Jardine, Paul A. DaSilva  
 PATENT ASSIGNEE(S): Pfizer, Inc., USA  
 SOURCE: PCT Int. Appl., 50 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9621656	A1	19960718	WO 1995-IB286	19950424
W: CA, FI, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5552412	A	19960903	US 1995-369954	19950109
CA 2209925	AA	19960718	CA 1995-2209925	19950424
EP 802910	A1	19971029	EP 1995-914493	19950424
EP 802910	B1	20020313		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
JP 10503215	T2	19980324	JP 1995-521528	19950424
JP 2972347	B2	19991108		
EP 1151998	A1	20011107	EP 2001-120246	19950424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 214382	E	20020315	AT 1995-914493	19950424
SK 281992	B6	20010911	SK 1995-1648	19951222
IL 116643	A1	20000813	IL 1996-116643	19960101
IL 130761	A1	20001206	IL 1996-130761	19960101
RU 2130454	C1	19990520	RU 1996-100074	19960105
NO 9600081	A	19960710	NO 1996-81	19960108
CN 1136562	A	19961127	CN 1996-100634	19960108
CN 1059902	B	20001227		
LV 11460	B	19961220	LV 1996-4	19960108
ZA 9600095	A	19970708	ZA 1996-95	19960108
CZ 285085	B6	19990512	CZ 1996-55	19960108
PL 183474	B1	20020628	PL 1996-312182	19960108
AU 9640916	A1	19960718	AU 1996-40916	19960109
AU 700982	B2	19990114		
BR 9600079	A	19980127	BR 1996-79	19960109
US 6204286	B1	20010320	US 1997-849726	19970630
FI 9702903	A	19970708	FI 1997-2903	19970708
US 6153622	A	20001128	US 1998-141613	19980828
US 6441193	B1	20020827	US 1999-466034	19991217
US 2001025051	A1	20010927	US 2001-820158	20010328
US 2002132816	A1	20020919	US 2002-147725	20020516
PRIORITY APPLN. INFO.:			US 1995-369954	A1 19950109
			EP 1995-914493	A3 19950424
			WO 1995-IB286	W 19950424
			IL 1996-116643	A3 19960101
			US 1997-849726	A1 19970630
			US 1999-466034	A1 19991217
OTHER SOURCE(S):	MARPAT 125:195446			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. [I; A = CH<sub>2</sub>, (substituted) NH; B, D, E = CH, N; Y = (substituted) Ph, naphthyl, C3-8 cycloalkyl, etc.; Z1 = (substituted) SCH<sub>2</sub>CH<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>, etc.; G = (substituted) NH<sub>2</sub>, pyrrolidino, piperidino, etc.; e = 0-2], useful for treating or preventing obesity, **breast cancer**, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia and prostatic disease, were prepd. Thus, hydrogenation of nafoxidene.HCl (II.HCl) over palladium hydroxide/C in EtOH followed by treatment of the intermediate cis-III with BBr<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub> afforded cis-I [A = CH<sub>2</sub>; B, D, E = CH; Y = Ph; Z1 = OCH<sub>2</sub>CH<sub>2</sub>; G = pyrrolidino; e = 1; 2-OH]. Compds. I significantly (P < 0.05) decreased prostate wt. compared to control in male Sprague-Dawley rats.

IT 180915-78-0P 180915-79-1P 180915-83-7P  
180915-84-8P 180915-86-0P 180915-92-8P  
180915-93-9P 180916-14-7P 180916-15-8P  
180916-16-9P 181137-16-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)

L35 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1991:449032 HCAPLUS

DOCUMENT NUMBER: 115:49032

TITLE: Synthesis and biological behavior of a boronated analog of the antiestrogen U 23,469-M

AUTHOR(S): Wellmann, Folkert; Abraham, Ralph; Mueller, Rainer; Gabel, Detlef

CORPORATE SOURCE: Fachbereich Chem., Univ. Bremen, Bremen, D-2800/33, Germany


SOURCE: Zeitschrift fuer Naturforschung, C: Journal of Biosciences (1991), 46(3-4), 252-6

CODEN: ZNCBDA; ISSN: 0341-0382

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB The title compd. I (R = decachloro-o-carboranyl) was prepd., for possible use in neutron capture therapy of estrogen receptor-pos. tumors. This compd. showed a large, non-specific uptake in ZR 75-1 **breast cancer**-derived cells. It partially inhibited the uptake of

estradiol in these cells. Accumulation in the cells at physiol. obtainable concns. was, however, too low to envisage a therapeutic effect following thermal neutron irradiation.

IT 98537-27-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. and radio-sensitizing antitumor activity of)

L35 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:198542 HCAPLUS

DOCUMENT NUMBER: 108:198542

TITLE: Estrogen and antiestrogen interaction with estrogen receptor of MCF-7 cells - relationship between processing and estrogenicity

AUTHOR(S): Gyling, M.; Leclercq, G.

CORPORATE SOURCE: Institut Jules Bordet, 1'Univ. Libre, Brussels, Belg.

SOURCE: Journal of Steroid Biochemistry (1988), 29(1), 1-8  
CODEN: JSTBBK; ISSN: 0022-4731

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Overnight preincubation of MCF-7 cells with 2 .times. 10-10M estradiol (E2) produced a dramatic redn. of their specific [3H]E2 binding capacity. Scatchard plot anal. revealed that this loss of estrogen receptor (ER) concn., usually termed processing, occurred without any modification of binding properties of the unprocessed receptors. Direct measurement of ER gave residual receptor concns. close to those established by binding assay, indicating that processing involved the loss of at least 1 epitope other than the steroid binding site. Incubation with increasing amts. of E2 (0.1 to 5 .times. 10-10M) resulted in an increasing redn. of binding capacity, indicating that the extent of processing was assocd. with the hormone concn. Steroidal estrogens other than E2 as well as antiestrogens of the triphenylethylene category behaved similarly in this regard, although the latter compds. usually acted only when at higher concns. The processing capacity of a large series of ligands was compared with the corresponding binding affinity for ER as assessed by classical competitive inhibition of [3H]E2 binding in both cytosol and whole cells. For steroidal estrogens, a large spectrum of concordant values was found which correlated with the known uterotrophic activity of the compds. However, weak estrogen and antiestrogens of the triphenylethylene category displayed low processing capacities which were in the order of magnitude of the binding affinities established in whole cells; these values were considerably lower than the corresponding values measured in the cytosol. These observations are consistent with the concept that the capacity of a ligand to process ER is related to its agonistic activity. They also support the hypothesis (Stoessel, S.; Leclercq, G. 1986) that assessment of the ability of a ligand to inhibit the binding of [3H]E2 in whole cells provides an est. of its agonistic activity, an est. which can not be established in the corresponding cytosol assay.

IT 107144-85-4

RL: BIOL (Biological study)

(estrogen receptor processing and mammary tumor cells response to, mol. structure in relation to)

✓ L35 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1982:97932 HCAPLUS

DOCUMENT NUMBER: 96:97932

TITLE: Effects of estrogens and antiestrogens on estrogen

receptor dynamics and the induction of progesterone  
receptor in MCF-7 human **breast**  
**cancer** cells

AUTHOR(S): Eckert, Richard L.; Katzenellenbogen, Benita S.  
CORPORATE SOURCE: Dep. Physiol. Biophys., Univ. Illinois, Urbana, IL,  
61801, USA  
SOURCE: Cancer Res. (1982), 42(1), 139-44  
CODEN: CNREA8; ISSN: 0008-5472  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The effects of the estrogens estradiol [50-28-2] and diethylstilbestrol [56-53-1] and the triphenylethylene antiestrogens CI628 [5863-35-4], CI628M [76313-96-7], U23,469 [36840-93-4], and U23,469M [72105-61-4] on intracellular estrogen receptor (ER) dynamics and growth and progesterone [57-83-0] receptor induction were examd. in MCF-7 human **breast cancer** cells. The relative binding affinities of the antiestrogens for cytoplasmic ER (ERC) were 1.0, 17, 0.04, and 34%, resp., in which the affinity of estradiol is considered 100%. Receptor-satg. concns. of CI628, CI628M, estradiol, and diethylstilbestrol (200, 10, 10, and 10 nM, resp.) caused complete ERC depletion and peak nuclear ER accumulation within 1 h. The nuclear receptor (ERN) sites declined thereafter and stabilized at near-control levels (1.2 pmol ERN/mg DNA) by 2-5 h, resulting in a net loss (processing) of approx. 50% of total cellular ER. In contrast, U23,469 (2000 nM) promoted complete depletion of ERC and quant. accumulation as ERN with 5 min, but the total ER content remained const. thereafter (no processing). U23,469M (60 nM) promoted complete ERC depletion and quant. nuclear accumulation, but the no. of ERN sites subsequently declined slowly to reach the control level by Day 5. Among these compds., estradiol and diethylstilbestrol (0.1-1000 nM) promoted a 600% increase in cytoplasmic progesterone receptor (5 days, control = 0.2 pmol/mg DNA). CI628M and U23,469M (1-10 nM) produced only a 300% increase, and U23,469 and CI628 (0.1-1000 nM) did not promote any increase. ER translocation to the nucleus and progesterone receptor induction appear to be related to ligand affinity. Antiestrogens differ substantially from one another in their dynamics of interaction with ER and in their abilities to stimulate increases in cellular progesterone receptor. Processing of ER by antiestrogens such as CI628 does not ensure subsequent induction of progesterone receptor; and an apparently complex relation exists between the presence and duration of hormone receptor complexes in the nucleus and the induction of progesterone receptor in MCF-7 cells. Since all 4 antiestrogens inhibit MCF-7 cell growth but differ in their ability to increase cellular progesterone receptor levels, these studies indicate that growth and progesterone receptor induction are phenomena that are independently modulated by antiestrogens in these human **breast cancer** cells.



IT 72105-61-4

RL: BIOL (Biological study)  
(estrogen and progesterone receptors of cytoplasm and nucleus of human mammary cancer cells response to)

L35 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2002 ACS

✓ ACCESSION NUMBER: 1981:41585 HCAPLUS  
DOCUMENT NUMBER: 94:41585  
TITLE: Antiestrogen action in estrogen target tissues:  
receptor interactions and antiestrogen metabolism  
AUTHOR(S): Katzenellenbogen, Benita S.; Katzenellenbogen, John  
A.; Eckert, Richard L.; Hayes, James R.; Robertson,

CORPORATE SOURCE: David W.; Tatee, Tochiyo; Tsai, Ten-lin S.  
 SOURCE: Dep. Physiol., Univ. Illinois, Urbana, IL, 61801, USA  
 Prog. Cancer Res. Ther. (1980), 14 (Horm. Cancer),  
 309-20  
 CODEN: PCRTDK; ISSN: 0145-3726  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB Uterine nuclear receptor antiestrogen complexes from rats injected with CI-628 (I citrate) [5863-35-4] sedimented in sucrose d. gradients in a similar manner to the receptor complex of rats treated with estradiol [50-28-2]. Nuclear antiestrogen- and estradiol-receptor complexes from DMBA-induced mammary tumors were also indistinguishable by sucrose d. gradient anal. The demethylated metabolites of I and U-23469 (II) [22845-61-0] had a much higher binding affinity for estrogen receptors in rat uterine cytosol and for nuclear or cytosol receptors in MCF-7 human **breast cancer** cells than did their resp. parent compds. Apparently, I and II are metabolized to compds. with a higher affinity for receptor and a faster onset of action. A discussion is included on the mol. aspects of the mode of action of antiestrogens.

IT **72105-61-4**  
 RL: PROC (Process)  
 (estrogen receptor binding of, in mammary tumors and uterus)

=>  
 =>

=> select hit rn 135 1-12  
 E1 THROUGH E41 ASSIGNED

=> fil reg  
 FILE 'REGISTRY' ENTERED AT 12:12:00 ON 29 OCT 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.



PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 OCT 2002 HIGHEST RN 466637-52-5  
DICTIONARY FILE UPDATES: 27 OCT 2002 HIGHEST RN 466637-52-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

=>

=> d his l36


(FILE 'HCAPLUS' ENTERED AT 12:11:07 ON 29 OCT 2002)  
SELECT HIT RN L35 1-12

FILE 'REGISTRY' ENTERED AT 12:12:00 ON 29 OCT 2002  
L36 41 S E1-E41

=> d ide can l36 1-41

L36 ANSWER 1 OF 41 REGISTRY COPYRIGHT 2002 ACS  
RN **366017-89-2** REGISTRY  
CN Butanoic acid, 4-[[2-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C28 H31 N O4  
SR CA  
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:303769

L36 ANSWER 2 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **366017-88-1** REGISTRY

CN 2-Pyrrolidinone, 1-[2-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C28 H29 N O3

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:303769

L36 ANSWER 3 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **366017-83-6** REGISTRY

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-1-methoxy-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C29 H33 N O3

SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:303769

L36 ANSWER 4 OF 41 REGISTRY COPYRIGHT 2002 ACS  
RN **366017-82-5** REGISTRY  
CN 1-Naphthalenol, 5,6,7,8-tetrahydro-2-methoxy-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C29 H33 N O3  
SR CA  
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:303769

L36 ANSWER 5 OF 41 REGISTRY COPYRIGHT 2002 ACS  
RN **366017-81-4** REGISTRY  
CN 1,2-Naphthalenediol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C28 H31 N O3  
SR CA  
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:303769

L36 ANSWER 6 OF 41 REGISTRY COPYRIGHT 2002 ACS  
RN **366017-71-2** REGISTRY  
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-3-methoxy-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C29 H33 N O3  
SR CA  
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:303769

L36 ANSWER 7 OF 41 REGISTRY COPYRIGHT 2002 ACS  
RN **366017-70-1** REGISTRY  
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-3-methoxy-7-phenyl-8-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (7R,8S)-rel- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C29 H33 N O3  
SR CA  
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:303769

L36 ANSWER 8 OF 41 REGISTRY COPYRIGHT 2002 ACS  
RN **366017-69-8** REGISTRY  
CN 2,3-Naphthalenediol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C28 H31 N O3  
SR CA  
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Relative stereochemistry.






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:303769

L36 ANSWER 9 OF 41 REGISTRY COPYRIGHT 2002 ACS  
RN **351527-09-8** REGISTRY  
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C28 H31 N O2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:344497

REFERENCE 2: 135:142234

L36 ANSWER 10 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347983-38-4** REGISTRY

CN 2-Propenamide, N,N-dimethyl-3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-isoquinolinyl)phenyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 3-[4-(6-Hydroxy-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl]-N,N-dimethylacrylamide

FS 3D CONCORD

MF C26 H26 N2 O2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 11 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347983-34-0** REGISTRY

CN Morpholine, 4-[1-oxo-3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-isoquinolinyl)phenyl]-2-propenyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 3-[4-(6-Hydroxy-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-phenyl]-1-(morpholin-4-yl)propenone

FS 3D CONCORD

MF C28 H28 N2 O3

SR CA

LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550


L36 ANSWER 12 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347983-29-3** REGISTRY

CN Piperidine, 1-[1-oxo-3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-isoquinolinyl)phenyl]-2-propenyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3-[4-(6-Hydroxy-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-phenyl]-1-(piperidin-1-yl)propenone  
 FS 3D CONCORD  
 MF C29 H30 N2 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 13 OF 41 REGISTRY COPYRIGHT 2002 ACS  
 RN **347982-72-3** REGISTRY  
 CN 2-Propenamides, N,N-dimethyl-3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-isoquinolinyl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C26 H26 N2 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 14 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347982-67-6** REGISTRY

CN Morpholine, 4-[(2E)-1-oxo-3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-isoquinolinyl)phenyl]-2-propenyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (E)-3-[4-(6-Hydroxy-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl]-1-(morpholin-4-yl)-1-propenone


FS STEREOSEARCH

MF C28 H28 N2 O3

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 15 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347982-63-2** REGISTRY

CN 2-Propenamide, 3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-isoquinolinyl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (E)-3-[4-(6-Hydroxy-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl]acrylamide


FS STEREOSEARCH

MF C24 H22 N2 O2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 16 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347982-52-9** REGISTRY

CN Piperidine, 1-[(2E)-1-oxo-3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-isoquinolinyl)phenyl]-2-propenyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (E)-3-[4-(6-Hydroxy-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phenyl]-1-piperidin-1-ylpropenone


FS STEREOSEARCH

MF C29 H30 N2 O2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 17 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347982-40-5** REGISTRY

CN 6-Isoquinolinol, 1,2,3,4-tetrahydro-1-(4-iodophenyl)-2-phenyl- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 1-(4-Iodophenyl)-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol

FS 3D CONCORD

MF C21 H18 I N O

SR CA

LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 18 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347981-50-4** REGISTRY

CN 6-Isoquinolinol, 1-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-phenyl- (9CI)  
(CA INDEX NAME)

OTHER NAMES:


CN 1-(4-Chlorophenyl)-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol

FS 3D CONCORD

MF C21 H18 Cl N O

SR CA

LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 19 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347981-05-9** REGISTRY

CN 2-Propenoic acid, 3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-isoquinolinyl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3-[4-(6-Hydroxy-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-phenyl]-(E)-acrylic acid


FS STEREOSEARCH

MF C24 H21 N O3

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 20 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347981-01-5** REGISTRY

CN 2-Propenoic acid, 3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-isoquinolinyl)phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C26 H25 N O3

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 21 OF 41 REGISTRY COPYRIGHT 2002 ACS  
RN **347980-97-6** REGISTRY  
CN 2-Propenoic acid, 3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-isoquinolinyl)phenyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C25 H23 N O3  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 22 OF 41 REGISTRY COPYRIGHT 2002 ACS  
RN **347980-83-0** REGISTRY  
CN 6-Isoquinolinol, 1,2,3,4-tetrahydro-1,2-diphenyl- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 1,2-Diphenyl-1,2,3,4-tetrahydroisoquinolin-6-ol  
FS 3D CONCORD  
MF C21 H19 N O  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 23 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347980-59-0** REGISTRY

CN 6-Isoquinolinol, 1,2,3,4-tetrahydro-1-(4-hydroxyphenyl)-2-phenyl- (9CI)  
(CA INDEX NAME)

OTHER NAMES:


CN 1-(4-Hydroxyphenyl)-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-ol

FS 3D CONCORD

MF C21 H19 N O2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 24 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347980-37-4** REGISTRY

CN 6-Isoquinolinol, 2-cyclohexyl-1,2,3,4-tetrahydro-1-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


OTHER NAMES:

CN 2-Cyclohexyl-1-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-1,2,3,4-tetrahydroisoquinolin-6-ol

FS 3D CONCORD

MF C27 H36 N2 O2

SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 25 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347980-32-9** REGISTRY

CN 6-Isoquinolinol, 2-(4,4-dimethylcyclohexyl)-1,2,3,4-tetrahydro-1-[4-(2-(1-pyrrolidinyl)ethoxy)phenyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 2-(4,4-Dimethylcyclohexyl)-1-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-1,2,3,4-tetrahydroisoquinolin-6-ol

FS 3D CONCORD

MF C29 H40 N2 O2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 26 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **347980-26-1** REGISTRY

CN 6-Isoquinolinol, 1,2,3,4-tetrahydro-1-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 1-[4-(2-(Pyrrolidin-1-yl)ethoxy)phenyl]-2-(tetrahydropyran-4-yl)-1,2,3,4-tetrahydroisoquinolin-6-ol

FS 3D CONCORD

MF C26 H34 N2 O3

SR CA

LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:92550

L36 ANSWER 27 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **193274-89-4** REGISTRY

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[6-[2-(1-pyrrolidinyl)ethoxy]-3-pyridinyl]-, (5R,6R)-rel- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[6-[2-(1-pyrrolidinyl)ethoxy]-3-pyridinyl]-, cis-


FS STEREOSEARCH

MF C27 H30 N2 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


18 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 18 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:180782  
 REFERENCE 2: 135:142234  
 REFERENCE 3: 135:117261  
 REFERENCE 4: 133:100053  
 REFERENCE 5: 133:100052  
 REFERENCE 6: 132:347946  
 REFERENCE 7: 132:203148  
 REFERENCE 8: 132:132346  
 REFERENCE 9: 130:311694  
 REFERENCE 10: 130:311531

L36 ANSWER 28 OF 41 REGISTRY COPYRIGHT 2002 ACS  
 RN **181137-16-6** REGISTRY  
 CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[6-[2-(1-pyrrolidinyl)ethoxy]-3-pyridinyl]-, (5S-cis)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C27 H30 N2 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:195446

L36 ANSWER 29 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **180916-16-9** REGISTRY

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R-cis)-

OTHER NAMES:

CN Lasofoxifene

FS STEREOSEARCH


MF C28 H31 N O2

CI COM

SR CA

LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

48 REFERENCES IN FILE CA (1962 TO DATE)  
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 49 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:16062  
 REFERENCE 2: 136:363955  
 REFERENCE 3: 136:335264  
 REFERENCE 4: 136:319399  
 REFERENCE 5: 136:273189  
 REFERENCE 6: 136:226440  
 REFERENCE 7: 136:11197  
 REFERENCE 8: 135:370722  
 REFERENCE 9: 135:339282  
 REFERENCE 10: 135:303769

L36 ANSWER 30 OF 41 REGISTRY COPYRIGHT 2002 ACS  
 RN **180916-15-8** REGISTRY  
 CN 6-Isoquinolinol, 1,2,3,4-tetrahydro-2-phenyl-1-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C27 H30 N2 O2  
 CI COM  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

18 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 18 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:180782  
 REFERENCE 2: 135:117261  
 REFERENCE 3: 133:100053  
 REFERENCE 4: 133:100052  
 REFERENCE 5: 132:347946  
 REFERENCE 6: 132:203148  
 REFERENCE 7: 132:132346  
 REFERENCE 8: 130:311694  
 REFERENCE 9: 130:311531  
 REFERENCE 10: 130:95849

L36 ANSWER 31 OF 41 REGISTRY COPYRIGHT 2002 ACS  
 RN **180916-14-7** REGISTRY  
 CN 6-Isoquinolinol, 2-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C27 H29 F N2 O2  
 CI COM  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

19 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 19 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:180782  
 REFERENCE 2: 135:142234  
 REFERENCE 3: 135:117261  
 REFERENCE 4: 133:100053  
 REFERENCE 5: 133:100052  
 REFERENCE 6: 132:347946  
 REFERENCE 7: 132:203148  
 REFERENCE 8: 132:132346  
 REFERENCE 9: 130:311694  
 REFERENCE 10: 130:311531

L36 ANSWER 32 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **180915-93-9** REGISTRY

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5S,6R)- (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5S-cis)-

OTHER NAMES:

CN CP 335992  
FS STEREOSEARCH  
MF C28 H31 N O2  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry. Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1962 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:100727

REFERENCE 2: 132:193326

REFERENCE 3: 129:184100

REFERENCE 4: 125:195446

L36 ANSWER 33 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **180915-92-8** REGISTRY

CN 6-Isoquinolinol, 1,2,3,4-tetrahydro-2-(4-hydroxyphenyl)-1-[4-[2-(1-pyrrolidinylethoxy)phenyl]- (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C27 H30 N2 O3

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:195446

L36 ANSWER 34 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **180915-86-0** REGISTRY

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-(4-hydroxyphenyl)-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-(4-hydroxyphenyl)-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, cis-


FS STEREOSEARCH

MF C29 H33 N O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

18 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 18 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:180782  
 REFERENCE 2: 135:142234  
 REFERENCE 3: 135:117261  
 REFERENCE 4: 133:100053  
 REFERENCE 5: 133:100052  
 REFERENCE 6: 132:347946  
 REFERENCE 7: 132:132346  
 REFERENCE 8: 130:311694  
 REFERENCE 9: 130:311531  
 REFERENCE 10: 130:95849

L36 ANSWER 35 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **180915-84-8** REGISTRY

CN 2-Naphthalenol, 6-(4-fluorophenyl)-5,6,7,8-tetrahydro-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Naphthalenol, 6-(4-fluorophenyl)-5,6,7,8-tetrahydro-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, cis-


FS STEREOSEARCH

MF C29 H32 F N O2

SR      CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

19 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

19 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:180782

REFERENCE 2: 135:142234

REFERENCE 3: 135:117261

REFERENCE 4: 133:100053

REFERENCE 5: 133:100052

REFERENCE 6: 132:347946

REFERENCE 7: 132:203148

REFERENCE 8: 132:132346

REFERENCE 9: 130:311694

REFERENCE 10: 130:311531

L36 ANSWER 36 OF 41 REGISTRY COPYRIGHT 2002 ACS


RN 180915-83-7 REGISTRY

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[6-[2-(1-



pyrrolidinyl)ethoxy]-3-pyridinyl]-, (5R-cis)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C27 H30 N2 O2  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 125:195446

L36 ANSWER 37 OF 41 REGISTRY COPYRIGHT 2002 ACS  
 RN 180915-79-1 REGISTRY  
 CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6R)-rel- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, trans-  
 FS STEREOSEARCH  
 MF C28 H31 N O2  
 CI COM  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 129:184100

REFERENCE 2: 125:195446

L36 ANSWER 38 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **180915-78-0** REGISTRY

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, cis-

OTHER NAMES:

CN CP 319609

FS STEREOSEARCH


MF C28 H31 N O2

CI COM

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

25 REFERENCES IN FILE CA (1962 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 25 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:119650  
 REFERENCE 2: 135:262237  
 REFERENCE 3: 135:180782  
 REFERENCE 4: 135:142234  
 REFERENCE 5: 135:117261  
 REFERENCE 6: 134:100727  
 REFERENCE 7: 133:100053  
 REFERENCE 8: 133:100052  
 REFERENCE 9: 132:347946  
 REFERENCE 10: 132:203148

L36 ANSWER 39 OF 41 REGISTRY COPYRIGHT 2002 ACS  
 RN 107144-85-4 REGISTRY  
 CN 1,3-Butanediol, 4-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenoxy]-(9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C26 H28 O4  
 SR CA  
 LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 108:198542

REFERENCE 2: 106:116021

L36 ANSWER 40 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN **98537-27-0** REGISTRY


CN 1,2-Dicarbadodecaborane(12)-1-ethanol, 3,4,5,6,7,8,9,10,11,12-decachloro-.alpha.-[[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)

MF C27 H26 B10 Cl10 O3

SR CA

LC STN Files: CA, CANCERLIT, CAPLUS, MEDLINE, TOXCENTER

PAGE 1-A



PAGE 2-A



2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 115:49032

REFERENCE 2: 103:137797

L36 ANSWER 41 OF 41 REGISTRY COPYRIGHT 2002 ACS

RN 72105-61-4 REGISTRY

CN 1,2-Propanediol, 3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenoxy]- (9CI) (CA INDEX NAME)


OTHER NAMES:

CN U 23469M

FS 3D CONCORD

MF C25 H26 O4

LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, TOXCENTER  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1962 TO DATE)  
5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 96:97932  
REFERENCE 2: 94:202868  
REFERENCE 3: 94:96523  
REFERENCE 4: 94:41585  
REFERENCE 5: 92:16102

=>  
=>

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 12:13:04 ON 29 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 29 Oct 2002 VOL 137 ISS 18
FILE LAST UPDATED: 28 Oct 2002 (20021028/ED)
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

```
=> d stat que 138 nos
L15 STR
L16 STR
L17 STR
L18 STR
L29 SCR 2039 OR 2127 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 O
R 2051 OR 2043
L31 17 SEA FILE=REGISTRY SSS FUL L15 OR L16 OR L18
L32 74 SEA FILE=REGISTRY SSS FUL L17 NOT L29
L33 79 SEA FILE=REGISTRY ABB=ON PLU=ON L31 OR L32
L34 83 SEA FILE=HCAPLUS ABB=ON PLU=ON L33
L35 12 SEA FILE=HCAPLUS ABB=ON PLU=ON L34 AND (BREAST(W)CANCER)
L37 10 SEA FILE=HCAPLUS ABB=ON PLU=ON L34(L) (?CANCER? OR ?TUMOR? OR
?NEOPLAS? OR ?MALIG?)
L38 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L37 NOT L35
```

```
=> d ibib abs hitrn 138 1-4
```

```
L38 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:573316 HCAPLUS
DOCUMENT NUMBER: 137:119650
TITLE: Method of treating certain cancers using an estrogen
agonist/antagonist
INVENTOR(S): Rosati, Robert Louis
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
```

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1226823	A2	20020731	EP 2002-250200	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 2001097121	A5	20020801	AU 2001-97121	20011206
CN 1366881	A	20020904	CN 2002-102519	20020125

PRIORITY APPLN. INFO.: US 2001-264566P P 20010126

OTHER SOURCE(S): MARPAT 137:119650

AB The invention provides methods of treating cancer of the liver, ovarian cancer, a desmoid tumor, glioma, pancreatic cancer, or renal cell carcinoma using an estrogen agonist/antagonist. The invention also provides kits that contain an estrogen agonist/antagonist for treating cancer of the liver, ovarian cancer, a desmoid tumor, glioma, pancreatic cancer, or renal cell carcinoma.

IT **180915-78-0 180915-78-0D**, derivs.

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (estrogen agonist/antagonist for **cancer** treatment)

L38 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:12736 HCAPLUS

DOCUMENT NUMBER: 136:226440

TITLE: LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model

AUTHOR(S): Cohen, Leonard A.; Pittman, Brian; Wang, Chung-Xiou; Aliaga, Cesar; Yu, Li; Moyer, James D.

CORPORATE SOURCE: American Health Foundation, Valhalla, NY, 10595, USA

SOURCE: Cancer Research (2001), 61(24), 8683-8688

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The N-nitroso-N-methylurea-induced rat mammary tumor model was used to conduct two types of studies: a prevention study designed to test the ability of the novel selective estrogen receptor modulator lasofoxifene (LAS) to inhibit the development of mammary tumors, and a treatment study designed to test the inhibitory effect of LAS on the growth of established tumors. The prevention study indicated that LAS markedly delayed the emergence of N-nitroso-N-methylurea-induced tumors to an extent similar to that obtained by the established antiestrogen tamoxifen (TAM). At the highest dose administered, both TAM and LAS reduced tumor incidence by 75% and total tumor no. by 90% relative to the controls. LAS also reduced the multiplicity of tumors, i.e., the mean no. of tumors per rat, and resulted in substantially smaller total tumor burden. In the treatment study, LAS significantly inhibited tumor growth compared with the controls. In addn., whereas none of the untreated tumors regressed completely over the exptl. period, 40% of LAS-treated tumors regressed by >50% at the highest dose (10 mg/kg daily). The results of this study in a rat mammary tumor model indicate that LAS has both chemopreventive and chemotherapeutic effects quant. comparable with those of TAM.

IT **180916-16-9**, Lasofoxifene

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL



(Biological study); USES (Uses)

(antitumor activity of lasofoxifene in N-nitroso-N-methylurea-induced rat mammary tumor model)

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:96107 HCAPLUS

DOCUMENT NUMBER: 130:158391

TITLE: Antitumor agents

INVENTOR(S): Nozaki, Hiroshi; Iinuma, Munekazu; Yamada, Masashi; Suma, Yukie

PATENT ASSIGNEE(S): Meiji Milk Products Co., Ltd., Japan

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9904776	A1	19990204	WO 1998-JP3273	19980722
W: CA, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 11035454	A2	19990209	JP 1997-195778	19970722
EP 998924	A1	20000510	EP 1998-933888	19980722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: JP 1997-195778 19970722  
WO 1998-JP3273 19980722

AB The invention relates to antitumor agents contg. as the active ingredient a compd. selected from among pallidol, miyabenol A, miyabenol C, .alpha.-viniferin, kobophenol A, 4,4-(1,3-butadiene-1,4-diyl)bisphenol, leachianol A, leachianol B, leachianol F, leachianol G, hopeaphenol and davidiol A and salts thereof. The active ingredients can be extd. from plants such as kobresia and sophora. Because of having excellent topoisomerase II inhibitory effects, these compds. are usable as antitumor agents.

IT **164123-50-6P**, Leachianol F **164204-62-0P**, Leachianol G

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor agents extd. from plants)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1981:202868 HCAPLUS

DOCUMENT NUMBER: 94:202868

TITLE: Antitumor activities and estrogen receptor interactions of the metabolites of the antiestrogens CI628 and U23,469 in the 7,12-dimethylbenz(a)anthracene-induced rat mammary tumor system

AUTHOR(S): Rorke, Ellen A.; Katzenellenbogen, Benita S.

CORPORATE SOURCE: Sch. Basic. Med. Sci., Univ. Illinois, Urbana, IL,

61801, USA  
 SOURCE: Cancer Res. (1981), 41(4), 1257-62  
 CODEN: CNREA8; ISSN: 0008-5472  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The **antitumor** activities of the nonsteroidal antiestrogens .alpha.-[p-[2-(1-pyrrolidino)ethoxy]phenyl]-4-methoxy-.alpha.'-nitrostilbene (CI628) [10448-84-7] and cis-[3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy]-1,2-propanediol] (U23,469) [36840-93-4] are compared with their demethylated metabolite forms in the dimethylbenz(a)anthracene-induced rat mammary **tumor** system. These demethylated forms are generated in vivo and are selectively accumulated in the nuclear estrogen receptor fraction in preference to the parent compd.; thus, direct administration of the metabolites was investigated for eliciting **tumor** regression. The potencies of the parent antiestrogens and their demethylated forms .alpha.-[p-[2-(1-pyrrolidino)ethoxy]phenyl]-4-hydroxy-.alpha.'-nitrostilbene (CI628M) [76313-96-7] and cis-[3-[p-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthyl)-phenoxy]-1,2-propanediol] (U23,469M) [72105-61-4] were examd. for stimulating the regression of establishing dimethylbenz(a)anthracene-induced mammary **tumors**. The effects of these antiestrogens on estrogen receptors and peroxidase [9003-99-0] as a sp. marker for estrogen action in mammary **tumors** and in uteri of **tumor**-bearing animals were also monitored. In mammary **tumor** cytosol in vitro, the antiestrogens competed with [3H]estradiol for binding to estrogen receptor with affinities of 113% (CI628M), 5% (CI628), 31% (U23,469M), and 0.6% (U23,469), where the affinity of estradiol is considered to be 100%. All 4 antiestrogens were equally effective as antagonists of **tumor** growth in vivo. Administration of 25 or 100 .mu.g daily of either parent (CI628 and U23,469) or the demethylated (CI628M and U23,469M) antiestrogens elicited the regression of the majority of dimethylbenz(a)anthracene **tumors**, whereas low doses (2.5 .mu.g/day) of any of these 4 compds. had no effect on **tumor** growth. The 25- and 100-.mu.g doses of antiestrogens markedly reduced **tumor** cytoplasmic estrogen receptor levels, but they failed to elevate **tumor** peroxidase activity. Uterine wts. were decreased below the diestrus controls following treatment with 25- or 100-.mu.g daily doses of the antiestrogens; these treatments also resulted in the nuclear localization of .apprx.80% of the total estrogen receptors. Uterine peroxidase activity, which was high in diestrus control females, was reduced to 5-25% by the intermediate- or high-dose levels of antiestrogens. Although the demethylated antiestrogens have a 20-50-fold enhanced affinity for the mammary **tumor** estrogen receptor in vitro as compared to their parent compd. in vivo, where the parent compds. are rapidly converted to the demethylated metabolites, both forms are equally potent **antitumor** and antiuterotropic agents.  
 IT 72105-61-4  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (neoplasm-inhibiting activity of, estrogen receptor interactions in relation to)

=> select hit rn 138 1-4  
 E42 THROUGH E46 ASSIGNED

=> fil reg

FILE 'REGISTRY' ENTERED AT 12:14:45 ON 29 OCT 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 OCT 2002 HIGHEST RN 466637-52-5  
DICTIONARY FILE UPDATES: 27 OCT 2002 HIGHEST RN 466637-52-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s e42-e46

1 180915-78-0/BI  
(180915-78-0/RN)  
1 164123-50-6/BI  
(164123-50-6/RN)  
1 164204-62-0/BI  
(164204-62-0/RN)  
1 180916-16-9/BI  
(180916-16-9/RN)  
1 72105-61-4/BI  
(72105-61-4/RN)

L39 5 (180915-78-0/BI OR 164123-50-6/BI OR 164204-62-0/BI OR 180916-16-9/BI OR 72105-61-4/BI)

=> d ide can l39 1-5

L39 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2002 ACS

RN **180916-16-9** REGISTRY

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R-cis)-

OTHER NAMES:

CN Lasofoxifene

FS STEREOSEARCH


MF C28 H31 N O2

CI COM

SR CA

LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, DDFU,  
DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, SYNTHLINE, TOXCENTER, USAN,  
USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

48 REFERENCES IN FILE CA (1962 TO DATE)  
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 49 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:16062  
 REFERENCE 2: 136:363955  
 REFERENCE 3: 136:335264  
 REFERENCE 4: 136:319399  
 REFERENCE 5: 136:273189  
 REFERENCE 6: 136:226440  
 REFERENCE 7: 136:11197  
 REFERENCE 8: 135:370722  
 REFERENCE 9: 135:339282  
 REFERENCE 10: 135:303769

L39 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2002 ACS

RN **180915-78-0** REGISTRY

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, cis-

OTHER NAMES:

CN CP 319609

FS STEREOSEARCH  
MF C28 H31 N O2  
CI COM  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

25 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
25 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:119650  
REFERENCE 2: 135:262237  
REFERENCE 3: 135:180782  
REFERENCE 4: 135:142234  
REFERENCE 5: 135:117261  
REFERENCE 6: 134:100727  
REFERENCE 7: 133:100053  
REFERENCE 8: 133:100052  
REFERENCE 9: 132:347946  
REFERENCE 10: 132:203148

L39 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2002 ACS

RN **164204-62-0** REGISTRY  
 CN 1H-Indene-4,6-diol, 2-(3,5-dihydroxyphenyl)-2,3-dihydro-1-[(R)-hydroxy(4-hydroxyphenyl)methyl]-3-(4-hydroxyphenyl)-, (1R,2S,3R)- (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 1H-Indene-4,6-diol, 2-(3,5-dihydroxyphenyl)-2,3-dihydro-1-[hydroxy(4-hydroxyphenyl)methyl]-3-(4-hydroxyphenyl)-, [1R-[1.alpha.(R\*),2.beta.,3.alpha.]]-

OTHER NAMES:

CN Leachianol G  
 FS STEREOSEARCH  
 MF C28 H24 O7  
 SR CA  
 LC STN Files: AGRICOLA, CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1962 TO DATE)  
 3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 130:158391

REFERENCE 2: 123:193591

REFERENCE 3: 123:29606

L39 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2002 ACS

RN **164123-50-6** REGISTRY  
 CN 1H-Indene-4,6-diol, 2-(3,5-dihydroxyphenyl)-2,3-dihydro-1-[(S)-hydroxy(4-hydroxyphenyl)methyl]-3-(4-hydroxyphenyl)-, (1R,2S,3R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN 1H-Indene-4,6-diol, 2-(3,5-dihydroxyphenyl)-2,3-dihydro-1-[hydroxy(4-

hydroxyphenyl)methyl]-3-(4-hydroxyphenyl)-, [1R-[1.alpha.(S\*),2.beta.,3.alpha.]]-

OTHER NAMES:

CN Leachianol F  
FS STEREOSEARCH  
MF C28 H24 O7  
SR CA  
LC STN Files: AGRICOLA, CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1962 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:90512  
REFERENCE 2: 130:158391  
REFERENCE 3: 123:193591  
REFERENCE 4: 123:29606


L39 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2002 ACS

RN 72105-61-4 REGISTRY

CN 1,2-Propanediol, 3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenoxy]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN U 23469M  
FS 3D CONCORD  
MF C25 H26 O4  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, TOXCENTER  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1962 TO DATE)  
5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE	1:	96:97932
REFERENCE	2:	94:202868
REFERENCE	3:	94:96523
REFERENCE	4:	94:41585
REFERENCE	5:	92:16102